Dublin, Jan. 12, 2018 -- The "Thyroid Cancer Forecast in 21 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
Thyroid cancer is a cancer originating from follicular or parafollicular thyroid cells. It is a relatively rare cancer, but the most common of the endocrine system. The main clinical split is between differentiated and undifferentiated tumour types, with the majority being well-differentiated.
This report provides the current incident population for thyroid cancer across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Saudi Arabia, South Africa, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current incidence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight, several features of thyroid cancer patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of thyroid cancer include:
- Familial Adenomatous Polyposis
- Acromegaly
- Diabetes
- Multiple endocrine neoplasia syndromes
- Sipple syndrome
Reasons to Buy:
- Ability to quantify patient populations in global thyroid cancer market to target the development of future products, pricing strategies and launch plans.
- Further insight into the incidence of the subdivided types of thyroid cancer and identification of patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Better understanding of the impact of specific co-morbid conditions on the incident population of thyroid cancer patients.
- Identification of thyroid cancer patient sub-populations that require treatment.
- Better understanding of the specific markets that have the largest number of thyroid cancer patients.
Key Topics Covered:
- Introduction
- Cause of the Disease
- Risk Factors & Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key Comorbid Conditions / Features Associated With the Disease
- Methodology for Quantification of Patient Numbers
- Additional Data Available on Request
- Top-Line Incidence for Thyroid Cancer
- Features of Thyroid Cancer Patients
- Papillary Thyroid Cancer Patients
- Comorbidities of Thyroid Cancer Patients
- Abbreviations Used in the Report
- Other Services & Solutions
- Reports & Publications
- Online Epidemiology Databases
- Online Pharmaceutical Pricing Database
- References
- Appendix
For more information about this report visit https://www.researchandmarkets.com/research/zfnxr2/thyroid_cancer?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs


Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Amazon Explores AI Content Marketplace With Media Publishers
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 



